2,802 Shares in Johnson & Johnson (NYSE:JNJ) Purchased by American Alpha Advisors LLC

Key Points

• American Alpha Advisors LLC recently invested $465,000 in Johnson & Johnson, acquiring 2,802 shares in the first quarter.
• Johnson & Johnson's stock has a market cap of $417.61 billion and reported a quarterly earnings per share of $2.77, exceeding expectations.
• The company announced a new quarterly dividend of $1.30, representing an annualized yield of 3.0% and a payout ratio of 55.61%.

American Alpha Advisors LLC purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 2,802 shares of the company's stock, valued at approximately $465,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Highline Wealth Partners LLC increased its position in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares during the last quarter. von Borstel & Associates Inc. purchased a new position in shares of Johnson & Johnson in the 1st quarter worth about $49,000. Harvest Fund Management Co. Ltd purchased a new stake in Johnson & Johnson during the first quarter valued at about $52,000. Capital A Wealth Management LLC purchased a new stake in Johnson & Johnson in the fourth quarter worth $50,000. Finally, Pandora Wealth Inc. bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $65,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.4%

Shares of JNJ stock traded up $0.65 during mid-day trading on Monday, hitting $173.98. The stock had a trading volume of 7,208,197 shares, compared to its average volume of 9,486,962. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $174.60. The firm has a market capitalization of $418.99 billion, a P/E ratio of 18.61, a price-to-earnings-growth ratio of 2.21 and a beta of 0.41. The firm's 50-day moving average is $159.26 and its two-hundred day moving average is $157.60. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the business earned $2.82 EPS. On average, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on JNJ. Guggenheim reaffirmed a "neutral" rating and issued a $167.00 target price (up from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Barclays boosted their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Bank of America upped their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Thursday, July 17th. Finally, Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.